Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG Oncology RTOG 0618 trial
JAMA — Timmerman RD, et al. | October 08, 2018
In this single-arm phase 2 NRG Oncology Radiation Therapy Oncology Group 0618 study, researchers investigated the safety of noninvasive stereotactic body radiation therapy (SBRT) delivered on an outpatient basis in eradicating lung cancer. Further, they assessed its efficacy in curing selected patients with operable lung cancer, obviating the need for surgical resection. Findings revealed that, in addition to low treatment-related morbidity, SBRT was associated with a high targeted tumor control such that surgery for salvage was not generally needed. The study results, therefore, support formal comparisons of surgery and stereotactic radiotherapy for early-stage lung cancer.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.